Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and
lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical …

The classification of adenohypophysial neoplasms as “pituitary neuroendocrine
tumors”(PitNETs) was proposed in 2017 to reflect their characteristics as epithelial …

Background: Acromegaly results from a persistent excess in growth hormone with clinical
features that may be subtle or severe. The most common cause of acromegaly is a pituitary …

Growth hormone (GH)-secreting pituitary tumours represent the most genetically determined
pituitary tumour type. This is true both for germline and somatic mutations. Germline …

Context Artificial intelligence (AI), in particular machine learning (ML), may be used to
deeply analyze biomarkers of response to first-generation somatostatin receptor ligands (fg …

Purpose To determine whether biochemical responses to long-acting forms of first-
generation somatostatin analogue (SSA) therapy in patients with acromegaly could be …

Approximately 60% of acromegaly patients are not adequately controlled by first-generation
somatostatin receptor ligands. This multicenter retrospective study aimed to identify the most …

Molecular pathology has advanced our understanding of many tumors and offers
opportunities to identify novel therapies. In the pituitary, the field has uncovered several …

Radiomic analysis has emerged as a valuable tool for extracting quantitative features from
medical imaging data, providing in-depth insights into various contexts and diseases. By …

Simple Summary Acromegaly treatment consists of surgical, medical, and radiation therapy.
First-generation somatostatin receptor ligands are the mainstay of medical therapy, with …